Alzheimer’s therapies should target a particular gene, researchers say

Scientists at UCL say drug developers should focus on two risk-raising variants of the Apoe gene

New therapies for Alzheimer's disease should target a particular gene linked to the condition, according to researchers who said most cases would never arise if its harmful effects were neutralised.

The call to action follows the arrival of the first wave of drugs that aim to treat Alzheimer's patients by removing toxic proteins from the brain. While the drugs slow the disease down, the benefits are minor, and they have been rejected for widespread use by the UK's National Institute for Health and Care Excellence (Nice).